Puja Patel

https://assets.montefioreeinstein.org/profiles/images/physphoto/Patel_Puja_MD_420x504.jpg

First Name

Puja

Last Name

Patel

NPI

1588808232

Faculty ID

14618

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

55302

Biography

<p>Puja Patel, MD, is an attending physician at Montefiore Einstein and Associate Professor, Neurology at our Albert Einstein College of Medicine. Dr. Patel's clinical focus is pediatric epilepsy, although she also sees patients with general pediatric neurological issues, including headaches, movement disorders, sleep concerns and developmental delay.</p><p>After obtaining her Bachelor of Arts in biology from Barnard College in 2005, Dr. Patel earned her Doctor of Medicine at the State University of New York Downstate Medical Center in 2009. She completed her internship and residency in pediatrics at NewYork-Presbyterian-Weill Cornell Medical Center in 2011. Following this, Dr. Patel came to Montefiore Einstein to continue her medical training, completing her pediatric neurology residency in 2014, a clinical neurophysiology fellowship in 2015 and a behavioral neurosciences fellowship in 2016.</p><p>Dr. Patel&rsquo;s research focuses on clinical seizure prediction in the pediatric population. She has been co-investigator in several clinical drug trials investigating new anti-seizure medications. Her work has been shared through invited presentations and peer-reviewed journals, books, chapters, review articles and abstracts. She is a reviewer for scientific journals, including <em>Epilepsy Research, the Journal of Neurological Sciences and Pediatric Neurology</em>, among others.</p><p>Dr. Patel is board certified by the American Board of Psychiatry and Neurology in Neurology with special competence in Child Neurology. She is a member of the Child Neurology Society and the American Epilepsy Society.</p>

Is Open Scheduling

On

Solomon L. Moshe

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c0b77720-090c-11ed-9bb9-9f5f9d7bb274.jpg

First Name

Solomon

Last Name

Moshe

NPI

1396820619

Faculty ID

6831

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoBodyText" style="margin: 1.95pt 8.45pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><strong>Solomon L. Mosh&eacute;, M.D., </strong>is the Charles Frost Chair in Neurosurgery and Neurology, and Professor of Neurology, Neuroscience, and Pediatrics at the Albert Einstein College of Medicine/Montefiore Medical Center in the Bronx, New York. He is also the Vice Chair of the Saul R. Korey Department of Neurology, Director of the Isabelle Rapin Child Neurology Division and Director of Clinical Neurophysiology. His area of expertise is in epilepsy and related disorders.</p>
<p class="MsoBodyText" style="margin: 1.95pt 8.45pt 0.0001pt 6pt; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;"><span style="font-size: 12pt;">Since 1979, his research has focused on understanding the mechanisms underlying age and sex-related differences in epilepsy in humans and animal models.&nbsp; Current research interests include studies on the role of subcortical circuitries involved in the control of seizures as a function of age and sex; the consequences of seizures on the developing brain and the development of models of catastrophic epilepsies. His laboratory has patented a model of infantile spasms that can be used to identify novel treatments. He is co principal investigator of a Center Without Walls grant on interdisciplinary research aimed at accelerating the development of disease modifying or prevention therapies for epilepsy following traumatic brain injuries. He is also involved in a large multicenter study examining the consequences of prolonged febrile seizures.&nbsp; He has over 600 publications as well as He has over 600 publications as well over 35 books and monographs.</span></p>
<p class="MsoNormal" style="margin: 0in; font-size: 11pt; font-family: Calibri, sans-serif;"><span style="font-size: 12pt;">over 35 books and monographs.</span></p>
<p class="MsoBodyText" style="margin: 0.55pt 0in 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;He has served as President of the International League Against Epilepsy (2009-2013), the American Epilepsy Society (2000-2001), the American Clinical Neurophysiology Society (1996-1997) and the Eastern Association of EEGers (1992-1994). He is the recipient of many awards and honors, including the Teacher-Investigator Development Award from NINDS; the 1995 Jacob Javits Neuroscience Investigator Award from NINDS; the 1984 Michael Prize for Achievements in Epilepsy Research; the 1990 American Epilepsy Society Research Award; the 1999 Ambassador for Epilepsy Award from the International League Against Epilepsy; the 2005 Gloor Award from the American Clinical Neurophysiology Society; the 2007 J.E. Purkyne Honorary Medal in Biomedical Research by the Czech Academy of Sciences; the 2008 Mentor of the Year Award from Albert Einstein College of Medicine; the 2010 Global and Awareness Award from CURE, Citizens United for Research in Epilepsy; the First 2012 Saul R. Korey Award in Translational Science and Medicine, Albert Einstein College of Medicine and the 2017 Bernard Sachs Award from the Child Neurology Society, <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">and the 2023 Lifetime Achievement Award from the International League against Epilepsy.</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">He has been asked to deliver over 50 several keynote lectures.</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: red;">&nbsp;</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Clinical Focus:</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Mosh&eacute; focuses on helping people with epilepsy and related conditions with a special emphasis on children and adolescents.</p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: red;">&nbsp;</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;"><span style="color: #002060;">Research focus</span></p>
<p class="MsoBodyText" style="margin: 0.05pt 5.85pt 0.0001pt 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr Mosh&eacute; has focused on translational research to understand the mechanisms underlying age and sex-related differences in epilepsy in humans and animal models. The main goals are to develop individualized treatments today and to prevent and cure epilepsy tomorrow. Current projects include the development of effective means to predict and treat epilepsy after traumatic brain injury and the development of specialized treatments for infants and children with epilepsy.</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr.&nbsp;Mosh&eacute; is an authority on the mechanisms that underlie the development of epilepsy and on the consequences of the disease in infants and children.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">A translational scientist, Dr. Mosh&eacute; has developed and patented an animal model that replicates human infantile spasms, which can be used to identify novel treatments of this devastating condition. Dr. Mosh&eacute; has served as President of the International League Against Epilepsy, American Epilepsy Society, the American Clinical Neurophysiology Society, and the Eastern Association of Electroencephalographers.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr. Mosh&eacute; is actively involved in several large, multicenter studies examining the outcomes of prolonged febrile seizure to identify predictive biomarkers of the course of these conditions and response to treatment.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;">Dr. Mosh&eacute;&nbsp;has received numerous honors and awards, including the American Epilepsy Society Research Recognition Award,&nbsp;Jacob Javitz Neuroscience Investigator Award from the National Institutes of Health, the Michael Prize,&nbsp;&nbsp;American Epilepsy Society research award, the CURE (Citizens United for Research in Epilepsy)&nbsp;&nbsp;Global Awareness Award for leadership in raising the international profile of epilepsy<strong>,&nbsp;</strong>the Pierre Gloor Award of the American Clinical Neurophysiology Society, and the J.E. Purkyne Honorary Medal for Merit in the BioMedical Sciences of the Czech Academy of Sciences. He is an elected member of the American Neurological Association and the American Pediatric Society. &nbsp;</span></p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Mosh&eacute; focuses on helping people with epilepsy and related conditions with a special emphasis on children and adolescents

Research Focus

Dr. Mosh&eacute; has focused on translational research to understand the mechanisms underlying age and sex-related differences in epilepsy in human and animal models. The main goals are to develop individualized treatments today and to prevent and cure epilepsy tomorrow. Current projects include the development of effective means to predict and treat epilepsy after traumatic brain injury and the development of specialized treatments for infants and children with epilepsy.

Elsevier Profile

Selected Publications

<ol>
<li>&nbsp;<span style="font-size: 11pt; font-family: Arial, sans-serif;">Katsarou A, Mosh&eacute; SL, Galanopoulou AS.&nbsp; Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders.&nbsp;&nbsp; Epilepsia Open 3: 284-306 (2017). PMID: 29062978</span></li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Moshe SL.&nbsp; The 2017 Sachs lecture: Kindling knowledge in Epilepsy.&nbsp; Pediatric Neurology 85: 5-12 (2018).&nbsp; PMID: 29958806</span></li>
<li>Saletti PG, Ali I, Casillas-Espinonsa PM, Semple BD, Lisgaras C, Moshe SL, Galanopoulou AS. In search of antiepileptogenic treatments for post-traumatic epilepsy.&nbsp; Neurobiology of Disease 123: 86-99 (2019).&nbsp; PMID: 29936231</li>
<li>Correa DJ, Kwon C, Connors S, Fureman B, Whittemore V, Jette N, Mathern G and Moshe SL.&nbsp;&nbsp; For the EpiBioS4RX Public Engagement Core.&nbsp;&nbsp; Applying participatory action research in traumatic brain injury studies to prevent post-traumatic epilepsy.&nbsp;&nbsp; Neurobiology of Disease 123: 137-144 (2019).&nbsp; PMID: 30031158</li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Molinero I, Galanopoulou AS and Moshe SL.&nbsp;&nbsp; Rodent models: Where it all started with these &ldquo;truths&rdquo;.&nbsp;&nbsp; European Journal of Paediatric Neurology 61-65 (2020) PMID: 31875833</span></li>
<li><span style="font-size: 11pt; font-family: Arial, sans-serif;">Ozlem A, Briggs S, Mowrey W, Moshe SL, Galanopoulou AS&nbsp;&nbsp; Antiepiletogenic effects of rapamycin in a model of infantile spasms due to structural lesions.&nbsp;&nbsp; Epilepsia, 62,1985-1999, (2021) PMID: 34212374</span></li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Zuberi S, Wirrell E, Yozawitz E, Wilmshurst J, Specchi N, Riney K, Pressler R, Auvin S, Samia P, Hirsch E, Galicchio S, Triki C, Snead O, Wiebe S, Cross H, Tinuper P, Scheffer I, Perucca E and Moshe SL.&nbsp;&nbsp; ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1349-1397 (2022) PMID: 35503712</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Hirsch E, French J, Scheffer I, Bogacz A, Alsaadi T, Sperling M, Abdulla F, Zuberi S, Trinka E, Specchio N, Somerville E, Samia P, Riney K, Nabbout R, Jain S, Wilmshurst J, Auvin S, Wiebe S, Perucca E, Moshe SL, Tinuper P and Wirrell E.&nbsp; ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1475-1499 (2022) PMID: 35503716</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Specchio N, Wirrell E, Scheffer I, Nabbout R, Riney K, Samia P, Guerreiro M, Gwer S, Zuberi S, Wilmshurst J, Yozawitz E, Pressler R, Hirsch E, Wiebe S, Cross H, Perucca E, Moshe SL, Tinuper P and Auvin S.&nbsp; International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.&nbsp; Epilepsia, 63, 1398-1442 (2022) PMID: 35503717</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">&nbsp;Riney K, Bogacz A, Somerville E, Hirsch E, Nabbout R, Scheffer I, Zuberi S, Alsaadi T, Jain S, French J, Specchio N, Trinka E, Wiebe S, Auvin S, Cabral-Lin L, Naiddo A, Perucca E, Moshe SL, Wirrell E and Tinuper P.&nbsp; International League Againist Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions.&nbsp;&nbsp; Epilespia, 63, 1443-1474 (2022) PMID: 35503725</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Wirrell E, Nabbout R, Scheffer I, Alsaadi T, Bogacz A, French J, Hirsch E, Jain S, Kaneko S, Riney K, Samia P, Snead O, Somerville E, Specchio N, Trinka E, Zuberi S, Balestrini S, Wiebe S, Cross H, Perucca E, Moshe SL and Tinuper P.&nbsp;&nbsp; Methodology for classification and definition of epilepsy syndromes with list of syndroms: Report of the ILAE Task Force on Nosology and Definitions.&nbsp;&nbsp; Epilepsia, 63, 1333-1348 (2022) PMID: 35503715</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Saletti P, Casillas-Espinosa P, Lisgaras C, Mowrey W, Li Q, Liu W, Brady R, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine E, Coles L, Cloyd J, Shultz S, Mosh&eacute; SL, O&rsquo;Brien T, Galanopoulou AS for the EpiBioS4RX Group.&nbsp;&nbsp;&nbsp; TAU phosphorylation patterns in the rat cerebral cortex after traumatic brain injury and sodium selenate effects:&nbsp; An EpiBioS4Rx Project 2 study.&nbsp;&nbsp; Journal of Neurotrauma pgs 1-22, (2023.) &nbsp;PMID: 36950806</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Saletti P, Mowrey W, Liu W, Li Q, McCullough J, Aniceto R, Lin I-H, Eklund M, Casillas-Espinosa P, Ali I, Santana-Gomez C, Coles L, Shultz S, Jones N, Staba R, O&rsquo;Brien T, Mosh&eacute; SL, Agoston D, Galanopoulou AS for the EpiBioS4RX Study Group.&nbsp;&nbsp;&nbsp;&nbsp; Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam.&nbsp;&nbsp; Epilepsia Open pgs. 586-608 (2023) PMID: 37026764</span></p>
</li>
<li>
<p class="MsoNormal" style="margin: 0in; font-size: 10pt; font-family: 'Times New Roman', serif;"><span style="font-size: 11pt; font-family: Arial, sans-serif;">Coles L, Saletti P, Lisgaras C, Casillas-Espinosa P, Liu W, Li Q, Jones N, Shultz S, Ali I, Brady R, Yamakawa G, Hudson M, Silva J, Braine E, Mishra U, Cloyd J, O&rsquo;Brien T, Mosh&eacute; SL, Galanopoulou AS for the EpiBioS4RX Study Group.&nbsp;&nbsp; Levetiracetam Pharmacokinetics and Brain Uptake in a Lateral Fluid Percussion Injury Rat Model.&nbsp;&nbsp; <span style="background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Journal of Pharmacology and Experimental Therapeutics pgs 1-30, (2023). &nbsp;PMID:</span> </span><span style="font-size: 11pt; font-family: Arial, sans-serif; color: #212121;">37316328</span></p>
</li>
</ol>

EMR ID

3412

Biography

<p>Solomon L. Mosh&eacute;, MD, is Vice Chair of Neurology, Director of the Isabelle Rapin Child Neurology Division and Director of Clinical Neurophysiology at Montefiore. He is also the Charles Frost Chair in Neurosurgery and Neurology, Vice Chair, Saul R. Korey Department of Neurology, and Professor of Neurology, Neuroscience and Pediatrics at the Albert Einstein College of Medicine (Einstein). Dr. Mosh&eacute;&rsquo;s clinical focus is on epilepsy and electroencephalography with special emphasis on age-related influences on the expression, control and consequences of seizures.</p><p>After receiving his Doctor of Medicine from the National University of Athens School of Medicine in Greece in 1972, Dr. Mosh&eacute; began his post-doctoral training at the University Hospital of Maryland. He completed his internship and residency there in pediatrics in 1975. Following this, he pursued a pediatric neurology fellowship at Einstein from 1975 to 1978. He was a visiting epilepsy research fellow at the University of California Los Angeles in 1978, then completed a neurology and neuroscience research fellowship at Einstein in 1979. He was a guest scholar with the EEG department at Columbia Presbyterian Medical Center from 1980 to 198, and with the seizure unit at Children&rsquo;s Hospital in Boston in 1980.</p><p>Dr. Mosh&eacute;&rsquo;s research focuses on understanding the mechanisms underlying differences in epilepsy in humans and animal models. His laboratory has developed and patented a novel model of human infantile spasms that can be used to identify novel treatments of this devastating condition. He also investigates the consequences of prolonged seizures and methods to accelerate the development of disease modifying or prevention therapies for post-traumatic epilepsy. His extensive body of work has been shared nationally and internationally through peer-reviewed publications, lectures and conferences. He is a member on several editorial boards including Neurobiology of Disease, Pediatric Neurology, Epileptic Disorders, and the Journal of Neurology & Psychology.</p><p>Dr. Mosh&eacute; has been recognized with numerous national and international honors and awards, including a 1995 Jacob Javits Neuroscience Investigator Award from the National Institute of Health, the first 2012 Saul R. Korey Award in Translational Science and Medicine, Albert Einstein College of Medicine; the 2017 Bernard Sachs Award from the Child Neurology Society, and election as a foreign member of the Russian Academy of Science in 2017. He is a member of many professional societies including the American Academy of Neurology, the Child Neurology Society, the American Epilepsy Society and the American Association for Advancement of Science.</p>

Is Open Scheduling

Off

Patrick A. LaSala

https://assets.montefioreeinstein.org/profiles/images/physphoto/Lasala_Patrick_MD_420x504.jpg

First Name

Patrick

Last Name

LaSala

NPI

1700980125

Faculty ID

6319

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Areas of Expertise

Expert Summary

<p>Dr. LaSala developed a program of computer–based localization techniques to refine surgical approaches to intracranial targets such as tumors and eplipetic zones to facilitate their removal. The methods are frequently minimally invasive and help safeguard surrounding vital brain structures. Dr. LaSala is the Department’s Chair of the Quality Improvement Committee and also sits on the Medical Centers Quality Improvement Peer review board. Dr. LaSala is a co-investigator on several multi-institution clinical research trials for the treatment of benign and malignant brain tumors.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3365

Is Open Scheduling

Off

Jisoon Kim

https://assets.montefioreeinstein.org/profiles/images/physphoto/Kim_Jisoon_MD_420x504.jpg

First Name

Jisoon

Last Name

Kim

NPI

1598024937

Faculty ID

15437

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

6376

Is Open Scheduling

Off

Christine Hung

https://assets.montefioreeinstein.org/profiles/images/13315-christine-hung.jpg

First Name

Christine

Last Name

Hung

NPI

1699932384

Faculty ID

13315

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5589

Is Open Scheduling

Off

Sheryl R. Haut

https://assets.montefioreeinstein.org/profiles/images/physphoto/Haut_Sheryl_MD_420x504.jpg

First Name

Sheryl

Last Name

Haut

NPI

1679658991

Faculty ID

5312

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program and Chief of Service, Neurology at Montefiore Einstein. She is the previous Chair of the North American Commission of the International League Against Epilepsy. Her research interests include: the temporal distribution of seizures, with emphasis on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is currently conducting electronic diary studies of seizure prediction and was the Principal Investigator of the first randomized controlled trial of stress management for refractory epilepsy using smartphone diaries. Dr. Haut has a Masters in Clinical Research Methods, and completed a K23 career development award from the NIH. She maintains an active adult epilepsy practice at Montefiore Medical Center, Moses Division.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Haut focuses on the special needs of epilepsy patients, such as pregnancy, stress, driving, work-related issues and issues in the elderly.

Research Focus

Dr. Haut's research is focused on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy.

Elsevier Profile

Selected Publications

<ol>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><!-- [if !supportLists]--><span style="mso-bidi-font-size: 12.0pt; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">Correa DJ, Labovitz DL, Milstein MJ, Monderer R, Haut SR. <strong><span style="font-weight: normal; mso-bidi-font-weight: bold;">Folding a neuroscience </span></strong></span><strong style="text-indent: -0.25in;"><span style="font-weight: normal; mso-bidi-font-weight: bold;">center into streamlined Covid-19 response teams: Lessons in origami. Neurology 2020, in press.</span></strong></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span></span><span class="author" style="text-indent: -0.25in;"><span lang="EN">Galanopoulou, AS</span></span><span lang="EN" style="text-indent: -0.25in;">, <span class="author">Ferastraoaru, V</span>, <span class="author">Correa, DJ</span>, </span><span lang="EN" style="text-indent: -0.25in;">Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler M, Ballaban-Gil K, Haut SR, Mosh&eacute; SL, Boro A. </span><span lang="EN" style="text-indent: -0.25in;">&nbsp;<span class="articletitle">EEG findings in acutely ill patients investigated for SARS</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">CoV-2/COVID</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">19: A small case series preliminary report</span></span><span lang="EN" style="text-indent: -0.25in;">. Epilepsia Open. <span class="pubyear">2020</span>; <span class="vol">5</span>: <span class="pagefirst">314</span>&ndash; <span class="pagelast">324</span>.&nbsp;</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Chiang S,&nbsp;</span></span></a><a name="baut0015"></a>Haut SR.&nbsp;<a name="baut0020"></a>Ferastaoaru V,&nbsp;<a name="baut0025"></a>Rao VR,&nbsp;<a name="baut0030"></a>&nbsp;M,&nbsp;<a name="baut0035"></a>Theodore WH,&nbsp;<a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Moss</span></span></a><a name="baut0040"></a>&nbsp;R,&nbsp;Goldenholz DM.&nbsp;<span class="title-text">Individualizing the definition of seizure clusters based on temporal clustering analysis. Epilepsy Res 2020;163:1-10.</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><strong style="text-indent: -0.25in;"><span style="font-weight: normal;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span></span></strong><strong style="text-indent: -0.25in;"><span style="border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in; font-weight: normal; mso-bidi-font-weight: bold;">Privitera M, Haut SR, Lipton RB, McGinley J, Cornes S. Seizure Self-prediction in a Randomized Controlled Trial of Stress Management. Neurology 2019;93(22):e2021-e2031</span></strong><span style="text-indent: -0.25in; color: windowtext;">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in; color: windowtext;">Ferastraoaru V, Goldenholz DM, Chiang S, Moss R, Theodore WH, Haut SR. Characteristics of large patient-reported outcomes: Where can one million seizures get us? Epilepsia Open. 2018 Jul 4;3(3):364-373&nbsp;</span></p>
</li>
<li>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp; </span><span lang="EN" style="text-indent: -0.25in;">Goldenholz DM, Goldenholz SR, Moss R, French J, Lowenstein D, Kuzniecky R, Haut S, Cristofaro S, Detyniecki K, Hixson J, Karoly P, Cook M, Strashny A, Theodore WH. Is seizure frequency variance a predictable quantity? Ann Clin Transl Neurol. 2018 Jan 9;5(2):201-207</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp; </span><span style="text-indent: -0.25in;">Haut SR, Lipton RB, Cornes S, Dwivedi AK, Wasson R, Cotton S, Strawn J, Privitera M. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. &nbsp;</span><span class="jrnl" style="text-indent: -0.25in;">Neurology</span><span style="text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">. 2018 Mar 13;90(11)</span></p>
<p style="margin-left: .25in; text-indent: -.25in; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in;">&nbsp;</p>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</li>
<li>Fisher RS, Cross JH, D&rsquo;Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian E, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017 Apr;58(4):531-542</li>
<li>Patel P, Ferastaoaru V, Gold D, Lipnick A, Jehle R, Haut SR. Clinical characterization of the pre-ictal state in the pediatric population: A caretaker&rsquo;s perspective. Epilepsy Behav. 2017 Apr 18;70(Pt A):193-197</li>
<li>Robbins MS, Haut SR, Lipton RB, Milstein MJ, Ocava LC, Ballaban-Gil K, Mosh&eacute; SL, Mehler MF. A dedicated scholarly research program in an adult and pediatric neurology residency program. Neurology. 2017 Apr 4;88(14):1366-1370</li>
<li>Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in Seizure emergencies: A systematic review. Epilepsy Behav. 2016 Oct;63:109-117.</li>
<li>Ferastraoaru V, Schulze-Bonhage A, Lipton RB, D&uuml;mpelmann M, Legatt AD, Blumberg J,&nbsp; Haut SR. Termination of seizure clusters is related to the duration of focal seizures. Epilepsia &nbsp;2016 Mar 31.</li>
<li>Pillai J, Haut SR, Masur D. Orbitofrontal cortex dysfunction in Psychogenic Non-Epileptic Seizures. A proposal for a two-factor model. Med Hypotheses. 2015 Apr;84(4):363-9</li>
<li>Haut SR. Seizure Clusters: Characteristics and Treatment. Curr Opin Neurol. 2015 Apr;28(2):143-50</li>
<li>Lipton RB,BuseDC, Hall CB, Tennen H, DeFreitas TA, Borkowski TM, Haut SR. Reduction in Perceived Stress as a Migraine Trigger: Testing the &ldquo;Let-down Headache&rdquo; Hypothesis. Neurology 2014; Apr 22;82(16):1395-401</li>
<li>Privitera M, Walters M, Lee I, Polak E, Fleck A, Schwieterman D, Haut SR. Characteristics of People with Stress Precipitated Seizures. Epilepsy Behav 2014 Oct;41:74-77</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Modeling seizure self-prediction: An e-diary study. Epilepsia 2013; Nov;54(11):1960-7.</li>
<li>Haut SR. Predicting seizures: Are we there yet? Epilepsy Currents 2013 Nov;13(6):276-8.</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Clinical features of the pre-ictal state: Mood changes and premonitory symptoms. Epilepsy and Behavior 2012, 23:415-421.</li>
<li>Pillai J, Haut SR. Patients with epilepsy and psychogenic non-epileptic seizures: An inpatient video-EEG monitoring study. Seizure. 2012, 21(1):24-7.</li>
<li>Schulze-BonhageA, Haut SR. Premonitory features and seizure self-prediction: Artifact or real? Epilepsy Res 2011, 97(3);231-235.</li>
<li>Haut SR, Lipton RBL. Predicting Seizures: A Behavioral Approach. Neurol Clinics 2009, 27(4);925-940.</li>
<li>Haut SR. Psychiatric History and Temporal Lobectomy Outcome: Looking to the Past to Predict the Future. Epilepsy Currents 2009, 9(5):1-3</li>
<li>Haut SR, Katz M, Masur J, Lipton RBL. Seizures in the Elderly: Impact on Mental Status, Mood and Sleep. Epilepsy and Behavior 2009;14(3):540-544.</li>
<li>Hall CB, Lipton RB, Tennen H, Haut SR. Early Follow-up Data From Seizure Diaries Can Be Used To Predict Subsequent Seizures in Same Cohort By Borrowing Strength Across Participants. Epilepsy and Behavior 2009;14(3);472-475.</li>
<li>Bower CM, Hays RD, Devinsky O, Spencer SS, Sperling MR, Haut S, Vassar S, Vickrey BG. Expectations Prior to Epilepsy Surgery: An Exploratory Comparison of Men and Women. Seizure 2009;18(3):228-231</li>
<li>Brody BD and Haut SR. Ending the Doctor-Patient Relationship in Neurology Practice. The Neurologist 2009;15(5): 277-81.</li>
<li>Haut SR, Hall CD, Masur J, Lipton RB. Seizure Occurrence: Precipitants and Prediction. Neurology 2007;69 1905-1910.</li>
<li>Lado F, Spiegel R, Masur J, Boro A, Haut SR. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epil Res 2007; 78(2-3);155-160</li>
<li>Chin PS, Berg AT, Spencer SS, Sperling MR, Haut S et al. Employment Outcomes Following Resective Epilepsy Surgery. Epilepsia 2007;Dec;48(12):2253-7.8.<span style="font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-size: 7.0pt; line-height: normal; font-variant: normal;">&nbsp; &nbsp;</span></li>
<li>Haut SR, Hall CD, LeValley A, Lipton RB. Can patients with epilepsy predict their seizures? Neurology, 2007; 68:262-266.</li>
<li>Spencer SS, Berg AT, Vickrey BG, Sperling MR, Bazil CW, Haut S, Langfitt JT, Walczak TS, Devinsky O; Multicenter Study of Epilepsy Surgery. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol. 2007 Oct;62(4):327-34</li>
<li>Haut SR, Bigal M, Lipton RB. Chronic Disorders With Episodic Manifestations: Focus on Epilepsy and Migraine. Lancet Neurology 2006;5:148-157.&nbsp;</li>
</ol>

EMR ID

3969

Biography

<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program at Montefiore. She has extensive experience treating all forms of epilepsy in young and older adults, and in tailoring treatments to the individual. She focuses on special needs such as pregnancy, stress, driving, work related issues, and issues in the elderly.</p> <p>Dr. Haut has an extensive research background, including a Masters of Clinical Research with Distinction from Albert Einstein College of Medicine. Her research interests focus on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is one of the first investigators to run a clinical trial of stress management for epilepsy, using smartphone diaries.</p> <p>Dr. Haut is the current Chair of the North American Commission of the International League Against Epilepsy, and is active nationally in the American Epilepsy Society, and the American Academy of Neurology, serving on committees of both organizations. She has authored more than 50 papers/book chapters on epilepsy, and has been featured in Top Doctors of NY annually since 2009. She maintains an active adult epilepsy practice at the Moses Campus.</p>

Is Open Scheduling

Off

Karen R. Ballaban-Gil

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c22b4660-58cd-11ee-9065-d1774810abb1.jpg

First Name

Karen

Last Name

Ballaban-Gil

NPI

1508941816

Faculty ID

642

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Karen Ballaban-Gil is Professor of Neurology and Pediatrics, the Director of the Child Neurology Residency Training Program and Director of Outpatient Child Neurology Services at the Albert Einstein College of Medicine. She graduated Magna Cum Laude from Union College and Cum Laude from Albany Medical College, in the 6 year combined B.S- M.D. program. Dr. Ballaban-Gil trained in general pediatrics at The Johns Hopkins Hospital, and trained in child neurology and clinical neurophysiology and epilepsy at the Albert Einstein College of Medicine. She received board certifications in pediatrics, neurology with special competence in child neurology , clinical neurophysiology and in epilepsy.</p>
<p><br />Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities. Her research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism, and other developmental disorders of higher cognitive functioning. In addition, she runs the Ketogenic Diet program for the management of intractable epilepsy at the Montefiore Medical Center - Comprehensive Epilepsy Center. Her publications include numerous papers on autism, epilepsy related language disorders, and the Ketogenic Diet.</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

3700

Biography

<p>Karen Ballaban-Gil, MD, is Director, Pediatric Epilepsy Center and Deputy Director, Division of Child Neurology at the Children&rsquo;s Hospital at Montefiore Einstein, and Professor, Pediatrics and Neurology at our Albert Einstein College of Medicine. Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities.</p><p>After receiving her Bachelor of Science at Union College in 1984, Dr. Ballaban-Gil earned her Doctor of Medicine in 1986 at the Albany Medical College. She began her postgraduate training at Johns Hopkins Hospital, completing two years as an intern and assistant resident in pediatrics before coming to Einstein, where she completed a residency in child neurology, followed by a fellowship in epilepsy and electrophysiology in 1991.</p><p>Dr. Ballaban-Gil&rsquo;s research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism and other developmental disorders of higher cognitive functioning. Her publications include numerous papers on autism, epilepsy related language disorders and the Ketogenic Diet. She has shared her work through national and international meetings, and has been a peer reviewer for a variety of medical journals, including <em>Epilepsia</em> and <em>Cephalgia</em>.</p><p>Dr. Ballaban-Gil is board certified by the American Board of Psychiatry and Neurology in Neurology with special competence in Child Neurology and with Certification in Epilepsy.</p>

Is Open Scheduling

Off

Aristea S. Galanopoulou

https://assets.montefioreeinstein.org/profiles/images/physphoto/Galanopoulou_Aristea_MD_420x504.jpg

First Name

Aristea

Last Name

Galanopoulou

NPI

1891870580

Faculty ID

6874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>The maturation of GABA_A<span class="apple-converted-space">&nbsp;</span>receptor-mediated signaling from depolarizing to inhibitory is an age-related process controlled by cation chloride cotransporters, such as KCC2. As a result, GABA exerts dual functions, being an important neurotrophic factor during early development and the principal inhibitory neurotransmitter of the mature central nervous system. In our laboratory we have been investigating the age mechanisms through which early life stressors and seizures may disrupt the normal patterns of brain development, by disrupting the neurotrophic effects of GABA. We are also studying methods to reverse these adverse processes. Furthermore, we are very interested in understanding how epileptogenesis proceeds in the developing brain and what is the specific role of GABA_A<span class="apple-converted-space">&nbsp;</span>receptors in this process.</p>
<p>To better understand the pathophysiology and design better methods to treat catastrophic early life epilepsies, we are developing and studying new models of early life epilepsy. These include models of symptomatic infantile spasms that recapitulate most of the features of the human condition. Several projects are under way to (a) elucidate the pathophysiology of infantile spasms, and (b) conduct preclinical trials to find better treatments for spasms and the associated comorbidities. Our studies have provided preclinical evidence for new potential treatments with disease modifying properties for these early life epileptic encephalopathies, such as mTOR inhibitor, carisbamate and a new vigabatrin analog.</p>
<p>Post-traumatic epilepsy is a common consequence of traumatic brain injury leading to high morbidity and morbidity. Our lab is participating in an international multicenter preclinical consortium, EpiBioS4Rx, leading efforts to develop better therapies for post-traumatic epilepsy. We use a rodent model of traumatic brain injury to identify targets and test for better therapies, through a combination of expression studies, in vivo behavioral and electrophysiologic monitoring and therapy screening to identify antiepileptogenic compounds. Furthermore, through a separate project, we are looking into factors predicting epilepsy and behavioral outcomes after traumatic brain injury.</p>
<p>Genetic etiologies are often identified in patients with epilepsies. Our lab has been investigating genes involved in lissencephaly associated epilepsies and developmental disorders as well as Rett syndrome which is due to MeCP2 gene mutations. Through the use of mouse models we have been investigating genotype-phenotype correlations and mechanisms involved with the ultimate goal of testing therapies.</p>
<p>Students interested in these projects will gain exposure to a variety of<span class="apple-converted-space">&nbsp;</span><em>in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>techniques that combine molecular biology<em>, in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>electrophysiology, histological, and behavioral studies and will be involved in projects with direct translational relevance to the clinical practice, i.e. identification of novel therapies.&nbsp;</p>
<p>&nbsp;</p>
<p><!--EndFragment--></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult epileptology, clinical neurophysiology

Research Focus

Post-traumatic epilepsy, developmental and epileptic encephalopathies, infantile spasms, GABA receptors, biomarkers, treatments for epilepsies

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS: &ldquo;Dissociated gender-specific effects of recurrent seizures on GABA signaling in CA1 pyramidal neurons: role of GABA_A&nbsp;receptors&rdquo;: J Neurosci 28 (7): 1557-67 (2008). PMID 18272677. https://www.jneurosci.org/content/28/7/1557.long</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Briggs SW, Mowrey W, Hall CB,<strong>&nbsp;</strong>Galanopoulou AS<strong>.&nbsp;</strong>CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia (2014) 55(1):94-102. PMID 24321005.&nbsp;https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12424&nbsp;</span>…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS&nbsp;and Mosh&eacute; SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease (2015): Neurobiol Dis. 2015 Jul;79:135-49. PMID 25968935.&nbsp;&nbsp;https://www.sciencedirect.com/science/article/pii/S096999611500162X?via…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, Mowrey WB, Liu W, Li Q, Shandra O, Moshe SL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update. Neurochem Res. 2017;42:1949-61.&nbsp;PMID 28462453.&nbsp;&nbsp;https://link.springer.com/article/10.1007%2Fs11064-017-2282-0</span></p…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, French JA, O&rsquo;Brien T, Simonato M. &ldquo;Harmonization in preclinical epilepsy research: a joint AES/ILAE translational initiative&rdquo;. Epilepsia (2017) 58 (Suppl 4):7-9. PMID 29105072. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13921</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Ono T, Wagenaar J, Giorgi FS et al, Galanopoulou AS. A companion to the preclinical common data elements and case report forms for rodent EEG studies. A report of the TASK3 EEG Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2018;3:90-103. PMID 30450486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210053/pdf/EPI4-3-90.pdf<…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Akman O, Raol YH, Auvin S et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Methodologic recommendations and possible interpretations of video-EEG recordings in immature&nbsp;rodents used as experimental controls: A&nbsp;TASK1-WG2 report of the ILAE/AES Joint Translational&nbsp;Task Force. Epilepsia Open. (2018)&nbsp;vol 3: 437-459. PMID 30525114. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276777/pdf/EPI4-3-437.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Li, Q, Liu W, Mosh&eacute; SL, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">&ldquo;Acquired parvalbumin-selective interneuronopathy in the multiple-hit model of infantile spasms: a putative basis for the partial responsiveness to vigabatrin analogs?&rdquo; Epilepsia Open (2018) vol 3 (S2): 155-164. PMID 30564774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293059/pdf/EPI4-3-155.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Salar S, Moshe SL, Galanopoulou AS. Metabolic etiologies in West syndrome.&nbsp;</span><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Epilepsia Open. 2018;3:134-66.</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;"><a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/29881795"><span lang="PT-BR">https://www.ncbi.nlm.nih.gov/pubmed/29881795</span></a></span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Ali I, Casillas-Espinosa PM et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis. (2019)&nbsp;123: 86-99 (2019).&nbsp; PMID: 29936231.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.sciencedirect.com/science/article/pii/S0969996118301980?via…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler MF, Ballaban-Gil K, Haut SR, Moshe SL, Boro A. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020;5:314-24.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/32537529">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Outcome of Hospitalized Parkinson's Disease Patients with and without COVID-19. Mov Disord Clin Pract. 2021;8:859-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34226870">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">13.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Akman O, Briggs SW, Mowrey WB, Moshe SL, Galanopoulou AS. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia. 2021;62:1985-99.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34212374">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">14.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Loscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer H, Wolf JA, Twyman R, Whittemore V, Wilcox KS, Klein B. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6:276-96.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34033232">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">15.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Kubova H, Auvin S, Mantegazza M, Barker-Haliski M, Galanopoulou AS, Reid CA, Semple BD.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3-WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2022.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35950641">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">16.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Medel-Matus JS, Lagishetty V, Santana-Gomez C, Shin D, Mowrey W, Staba RJ, Galanopoulou AS, Sankar R, Jacobs JP, Mazarati AM. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia. 2022;63:1835-48.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35366338">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">17.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Mowrey WB, Liu W, Li Q, McCullough J, Aniceto R, Lin IH, Eklund M, Casillas-Espinosa PM, Ali I, Santana-Gomez C, Coles L, Shultz SR, Jones N, Staba R, O'Brien TJ, Moshe SL, Agoston DV, Galanopoulou AS, EpiBio SRSG. Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam. Epilepsia Open. 2023;8:586-608.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37026764">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">18.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Coles L, Forcelli PA, Leclercq K, Katsarou AM, Klein BD, Potschka H, Koehling R, Harte-Hargrove L, Galanopoulou AS, Metcalf CS. Preclinical common data elements for general pharmacological studies (pharmacokinetic sample collection, tolerability, and drug administration). A report of the TASK3-WG1A General Pharmacology Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2023.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36896626">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">19.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023;103:433-513.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35951482">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">20.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Auvin S, Galanopoulou AS, Moshe SL, Potschka H, Rocha L, Walker MC. Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023;64:2891-908.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37676719">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">21.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Grandizoli Saletti P, Casillas-Espinosa PM, Panagiotis Lisgaras C, Bi Mowrey W, Li Q, Liu W, Brady RD, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine EL, Coles L, Cloyd JC, Jones NC, Shultz SR, Moshe SL, O'Brien TJ, Galanopoulou AS. Tau Phosphorylation Patterns in the Rat Cerebral Cortex After Traumatic Brain Injury and Sodium Selenate Effects: An Epibios4rx Project 2 Study. J Neurotrauma. 2024;41:222-43.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36950806">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">22.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Lucasius C, Grigorovsky V, Nariai H, Galanopoulou AS, Gursky J, Moshe SL, Bardakjian BL. Biomimetic Deep Learning Networks With Applications to Epileptic Spasms and Seizure Prediction. IEEE Trans Biomed Eng. 2024;71:1056-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37851549">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">23.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Samfira IMA, Galanopoulou AS, Nariai H, Gursky JM, Moshe SL, Bardakjian BL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open. 2024;9:122-37.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37743321">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">24.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, Felli AC, Cross JH, Galanopoulou AS, Jain S, Jiang Y, Kalviainen R, Lim SH, Meador KJ, Mogal Z, Nabbout R, Sofia F, Somerville E, Sperling MR, Triki C, Trinka E, Walker MC, Wiebe S, Wilmshurst JM, Wirrell E, Yacubian EM, Kapur J. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65:533-41.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38279786">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">25.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Pease M, Gupta K, Moshe SL, Correa DJ, Galanopoulou AS, Okonkwo DO, Gonzalez-Martinez J, Shutter L, Diaz-Arrastia R, Castellano JF.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Insights into epileptogenesis from post-traumatic epilepsy. Nat Rev Neurol. 2024;20:298-312.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38570704">https://www.ncbi.nlm.nih…;
<p></p>
<p class="MsoNormal" style="font-size: medium;"><span style="font-size: 9pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>

EMR ID

4043

Is Open Scheduling

Off

Victor Ferastraoaru

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ferastraoaru_Victor_MD_420x504.jpg

First Name

Victor

Last Name

Ferastraoaru

NPI

1851689798

Faculty ID

14637

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

54052

Is Open Scheduling

On

Emad N. Eskandar

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/1010cda0-b882-11ee-8618-fda8dc77c52b.jpg

First Name

Emad

Last Name

Eskandar

NPI

1972576239

Faculty ID

15647

CMO Specialties

Clinical Terms

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Clinical Interests: Epilepsy, Trigeminal neuralgia, Parkinson Disease, and Brain tumors</strong>.<br /> Dr. Eskandar specializes in the surgical diagnosis and treatment of epilepsy in both children and adults.&nbsp;&nbsp; He is a world-leader in this field, and has over 15 years of experience in utilizing the most current techniques. &nbsp;These techniques include keyhole surgery (minimal incision), stereotactic electro-encephalography (SEEG), minimally invasive foramen-ovale electrodes, vagal nerve stimulation, responsive neuro-stimulation (RNS or Neuropace), and laser ablation of epileptic areas. &nbsp;&nbsp;</p>
<p>In addition, Dr. Eskandar is an expert in the treatment of trigeminal neuralgia, an extremely painful condition affecting the face.&nbsp;&nbsp; He has vast experience in all the major therapeutic treatment modalities including micro-vascular decompression, percutaneous rhizotomy, and radiosurgery.&nbsp; He can provide comprehensive medical and surgical care for this debilitating condition.</p>
<p>Dr. Eskandar has vast experience in using deep brain stimulation (DBS) for the treatment of Parkinson Disease, Dystonia, Essential Tremor, and severe Obsessive-Compulsive Disorder.&nbsp;&nbsp; He employs different methods for surgery including awake-surgery with micro-electrode recordings, frameless surgery, and surgery under anesthesia using real-time imaging.</p>
<p>Finally, Dr. Eskandar treats all types of brain tumors including meningiomas, gliomas, low grade tumors, and metastatic brain tumors.&nbsp; He specializes in the use of advanced brain-imaging and brain-mapping techniques to minimize the risk of injury and to maximize tumor resection.&nbsp; Dr. Eskandar is a pioneer in brain mapping and has published many seminal papers on this topic.</p>
<p><strong>Research Interests</strong>: <br /> Dr. Eskandar also heads an active basic research laboratory investigating the Basal Ganglia, a group of centrally located nuclei in the brain.&nbsp;&nbsp; The Basal Ganglia play a central role in theories of learning, motivation, depression and drug addiction.&nbsp; His group uses microelectrode and electrochemical recordings to evaluate the role of the basal ganglia in both primates and humans performing complex behavioral tasks.&nbsp; The group also uses electrical stimulation to directly modulate neuronal activity during complex behaviors. This is a unique approach in that ideas from the laboratory can quickly be tested in the clinical arena and vice-versa.&nbsp; In addition, his group is actively working to develop the next generation of brain stimulators that will be MRI safe, use more intelligent technological interfaces and employ the latest innovations in miniaturization and battery technology.&nbsp;</p>
<p>The Eskandar lab has made numerous important scientific contributions.&nbsp; For example, one recent study, published in <em>Nature</em>, found that a part of the brain called the Cingulate Cortex plays an important role in adapting to varying degrees of cognitive difficulty.&nbsp; Another recent paper in <em>Nature Neuroscience,</em> found that delivering micro-stimulation in one part of the basal ganglia, the caudate nucleus, significantly increases the rate of learning beyond baseline rates.&nbsp; These findings suggest that the caudate plays a critical role in learning, and that learning can be enhanced to promote recovery after traumatic brain injury or stroke.&nbsp;</p>
<p><strong>Background:<br /> </strong>Dr. Eskandar received a Bachelor of Arts degree in chemistry from the University of Nebraska. He earned a medical degree at the University of Southern California, Los Angeles, and a master of business administration degree at the Sloan School of Management at the Massachusetts Institute of Technology. He was a neurological surgery resident at Massachusetts General Hospital in Boston, MA, and a neurophysiology fellow at Harvard Medical School.&nbsp;He previously, held the Charles Anthony Pappas endowed chair of Neurosurgery at Harvard Medical School where he also served as Professor of Neurosciences.&nbsp;</p>
<p>Dr. Eskandar is board-certified by the American Board of Neurological Surgery. He is a member of the American Association of Neurological Surgeons and the American Academy of Neurological Surgeons. He is the current President of the American Society for Stereotactic and Functional Neurosurgery.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<p>Emad N. Eskandar, MD, specializes in the surgical diagnosis and treatment of epilepsy in both children and adults. He is a world leader in this field, with more than 15 years of experience in utilizing the most current techniques. These techniques include keyhole surgery (minimal incision), stereotactic electro-encephalography (SEEG), minimally invasive foramen-ovale electrodes, vagal nerve stimulation, responsive neuro-stimulation (RNS or NeuroPace) and laser ablation of epileptic areas.</p><p>In addition, Dr. Eskandar is an expert in the treatment of trigeminal neuralgia, an extremely painful condition affecting the face. He has vast experience in all the major therapeutic treatment modalities, including micro-vascular decompression, percutaneous rhizotomy and radiosurgery. He can provide comprehensive medical and surgical care for this debilitating condition.</p><p>Dr. Eskandar also has long-standing expertise in using deep brain stimulation (DBS) for the treatment of Parkinson disease, dystonia, essential tremor and severe obsessive-compulsive disorder. Dr. Eskandar employs all current available techniques, including awake-surgery with micro-electrode recordings, frameless surgery and surgery under anesthesia using real-time imaging.</p><p>Finally, Dr. Eskandar treats all types of brain tumors, including meningiomas, gliomas, low-grade tumors and metastatic brain tumors. He specializes in the use of advanced brain-imaging and brain-mapping techniques to minimize the risk of injury and to maximize tumor resection. Dr. Eskandar is an expert in brain mapping and has published many seminal papers on this technique.</p>

Research Focus

<p>Dr. Eskandar heads an active basic research laboratory investigating the Basal Ganglia, a group of centrally located nuclei in the brain. The Basal Ganglia play a central role in theories of learning, motivation, depression and drug addiction. His group uses microelectrode and electrochemical recordings to evaluate the role of the basal ganglia in both primates and humans performing complex behavioral tasks. The group also uses electrical stimulation to directly modulate neuronal activity during complex behaviors. This is a unique approach in that ideas from the laboratory can quickly be tested in the clinical arena and vice-versa. In addition, his group is actively working to develop the next generation of brain stimulators that will be MRI safe, use more intelligent technological interfaces and employ the latest innovations in miniaturization and battery technology.</p>

Elsevier Profile

Selected Publications

<p><strong>Selected Publications from over 200</strong></p>
<ul>
<li>Martinez-Rubio C, Paulk AC, McDonald EJ, Widge AS, <strong>Eskandar EN</strong>. Multimodal Encoding of Novelty, Reward, and Learning in the Primate Nucleus Basalis of Meynert. <strong>J Neurosci.</strong> 2018 Feb 21;38(8):1942-1958<strong>. </strong></li>
<li>Herrington TM, Briscoe J, <strong>Eskandar E</strong>. Structural and Functional Network Dysfunction in Parkinson Disease. <strong>Radiology</strong>. 2017 Dec;285(3):725-727.</li>
<li>Asaad WF, Lauro PM, Perge JA, <strong>Eskandar EN</strong>. Prefrontal Neurons Encode a Solution to the Credit-Assignment Problem. <strong>J Neurosci</strong>. 2017 Jul 19;37(29):6995-7007.</li>
<li>Herrington TM, Cheng JJ, <strong>Eskandar EN</strong>. Mechanisms of deep brain stimulation. <strong>J </strong><strong>Neurophysiol</strong>. 2016 Jan 1;115(1):19-38.</li>
<li>Katnani HA, Patel SR, Kwon CS, Abdel-Aziz S, Gale JT, <strong>Eskandar EN</strong>. Temporally Coordinated Deep Brain Stimulation in the Dorsal and Ventral Striatum Synergistically Enhances Associative Learning. <strong>Sci Rep</strong>. 2016 Jan 4;6:18806.</li>
<li>Ishizawa Y, Ahmed OJ, Patel SR, Gale JT, Sierra-Mercado D, <strong>Brown EN</strong>, <strong>Eskandar&nbsp; EN</strong>. Dynamics of Propofol-Induced Loss of Consciousness Across Primate Neocortex.&nbsp; <strong>J Neurosci</strong>. 2016 Jul 20;36(29):7718-26.</li>
<li>Patel SR, Sheth SA, Martinez-Rubio C, Mian MK, Asaad WF, Gerrard JL, Kwon CS,&nbsp; Dougherty DD, Flaherty AW, Greenberg BD, Gale JT, Williams ZM, <strong>Eskandar EN</strong>. Studying task-related activity of individual neurons in the human brain. <strong>Nature Protocols</strong>. 2013 Apr 18;8(5):949-957.</li>
<li>Sheth S, Mian M, Patel S, Asaad W, Williams Z, Dougherty D, Bush G, <strong>Eskandar E</strong>.&nbsp; Human Dorsal Anterior Cingulate Neurons Mediate Behavioral Adaptation.&nbsp; <strong>Nature. </strong>2012 Aug 9;488(7410):218-21<strong>.</strong></li>
<li>Patel S, Sheth S, Mian M, Gale J, Dougherty D, Greenberg B, <strong>Eskandar E</strong>.&nbsp; Single neuronal responses during a financial decision-making task in the human nucleus accumbens.&nbsp; <strong>J Neuroscience</strong>, 2012 May 23;32(21):7311-5. PubMed PMID:22623676.</li>
<li>Mian MK, Sheth SA, Patel SR, Spiliopoulos K, <strong>Eskandar EN</strong>, Williams ZM. Encoding of Rules by Neurons in the Human Dorsolateral Prefrontal Cortex. <strong>Cereb Cortex.</strong> 2012 Nov 21. [Epub ahead of print] PubMed PMID: 23172774.</li>
<li>Sheth SA, Abuelem T, Gale JT, <strong>Eskandar EN</strong>. Basal ganglia neurons dynamically facilitate exploration during associative learning. <strong>J Neurosci</strong>. 2011. Mar 30;31(13):4878-85.</li>
<li>Asaad W<strong>, Eskandar, E. </strong>&nbsp;Encoding of both Positive and Negative Reward Prediction Errors by Neurons of the Primate Lateral Prefrontal Cortex and Caudate Nucleus.&nbsp; <strong>&nbsp;J. Neurosci. </strong>2011 Dec 7;31(49):17772-87<strong>. </strong></li>
<li>Truccolo W, Donoghue JA, Hochberg LR, <strong>Eskandar EN,</strong> Madsen JR, Anderson WS, <strong>Brown EN,</strong> Halgren E, Cash SS. Single-neuron dynamics in human focal epilepsy. <strong>Nat Neurosci</strong>. 2011 May;14(5):635-41.</li>
<li>Kramer MA, Eden UT, Kolaczyk ED, Zepeda R, <strong>Eskandar EN</strong>, <strong>Cash SS</strong>. Coalescence and fragmentation of cortical networks during focal seizures. <strong>J Neurosci</strong>. 2010 Jul 28;30(30):10076-85.</li>
<li>Williams ZM<strong>, Eskandar EN</strong>. Selective enhancement of associative learning by microstimulation of the anterior caudate.&nbsp; <strong>Nature Neurosci</strong>. 2006. 9(4):562-8.</li>
</ul>

EMR ID

11669

Biography

<p>Dr. Eskandar is a world-renowned neurosurgeon and a prominent neurosurgical leader. He is an expert in the management of Deep Brain Stimulation (DBS), brain tumors, epilepsy, trigeminal neuralgia and Parkinson Disease.</p><p>Dr. Eskandar received a Bachelor of Arts degree in chemistry from the University of Nebraska. He earned a medical degree at the University of Southern California, Los Angeles, and a master of business administration degree at the Sloan School of Management at the Massachusetts Institute of Technology. He was a neurological surgery resident at Massachusetts General Hospital in Boston, MA, and a neurophysiology fellow at Harvard Medical School.</p><p>Previously, he was the Charles Anthony Pappas endowed chair of Neurosurgery at Harvard Medical School where he also served as Professor of Neurosciences. He was a Neurosurgeon at Massachusetts General Hospital, where he also held several positions including Director of Functional Neurosurgery, Director of Neurosurgery Residency, Director of Movement Disorders Surgery Service and Director of Epilepsy Surgery Service.</p><p>Dr. Eskandar is board-certified by the American Board of Neurological Surgery. He is a member of the American Association of Neurological Surgeons and the American Academy of Neurological Surgeons. He is the current President of the American Society for Stereotactic and Functional Neurosurgery.</p>

Is Open Scheduling

On